Thompson, 477 patient HCQ late treatment RCT: 6% higher mortality [p=0.85] and 3% worse 7-point scale results [p=0.87] https://c19p.org/thompson
copied to clipboard
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID)
et al., NCT04332991 (Preprint)
Late stage (65% on oxygen at baseline) low-dose RCT, not showing significant differences with treatment.
|
risk of death, 6.2% higher, RR 1.06, p = 0.85, treatment 25 of 241 (10.4%), control 25 of 236 (10.6%), NNT 455, adjusted per study, odds ratio converted to relative risk, day 28.
|
|
risk of death, 51.0% higher, RR 1.51, p = 0.28, treatment 18 of 241 (7.5%), control 14 of 236 (5.9%), adjusted per study, odds ratio converted to relative risk, day 14.
|
|
risk of 7-point scale, 3.1% higher, OR 1.03, p = 0.87, treatment 241, control 236, day 28, RR approximated with OR.
|
|
risk of 7-point scale, 2.0% lower, OR 0.98, p = 0.91, treatment 241, control 236, day 14, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Thompson et al., 2/9/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 1 author.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.